Abstract:Background: Red blood cell membrane-coated nanoparticle (RBCm-NP) platform, which consist of natural RBCm and synthetic polymeric core, can extend circulation time in vivo with an improved biocompatibility and stability of this biomimetic nanocarrier. To achieve better bioavailability of antitumor drugs that were loaded in RBCm-NPs, the functionalization of coated RBCm with specific targeting ability is essential. Bispecific recombinant protein anti-EGFR-iRGD, containing both tumor penetrating peptide (internalizing RGD peptide) and EGFR single-domain antibody (sdAb), seems to be an optimal targeting ligand for RBCm-NPs in the treatment of multiple tumors, especially colorectal cancer with high EGFR expression. Materials and methods: We modified the anti-EGFR-iRGD recombinant protein on the surface of RBCm-NPs by lipid insertion method to construct iE-RBCm-PLGA NPs and confirmed the presentation of active tumor-targeting ability in colorectal cancer models with high EGFR expression when compared with RBCm-PLGA NPs. In addition, potential anti-tumor drug gambogic acid (GA) was loaded into the NPs to endow the antitumor efficiency of iE-RBCm-GA/PLGA NPs. It was simultaneously evaluated whether GA can reach better biocompatibility benefiting from the improved antitumor efficiency of iE-RBCm-GA/PLGA NPs in colorectal cancer models. Results: We successfully modified anti-EGFR-iRGD proteins on the surface of biomimetic NPs with integrated and stable "shell-core" structure. iE-RBCm-PLGA NPs showed its improved targeting ability in vitro (multicellular spheroids [MCS]) and in vivo (nude mice bearing tumors). Besides, no matter on short-term cell apoptosis at tumor site (terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling [TUNEL]) and long-term tumor inhibition, iE-RBCm-GA/PLGA NPs achieved better antitumor efficacy than free GA in spite of the similar effects of cytotoxicity and apoptosis to GA in vitro. Conclusion: We expect that the bispecific biomimetic nanocarrier can extend the clinical application of many other potential antitumor drugs similar to GA and become a novel drug carrier in the colorectal cancer treatment.

Modification of erythrocytes by internalizing Arg-Gly-Asp (iRGD) in boosting the curative effect of radiotherapy for gastric carcinoma

Modulating Tumour Vascular Normalisation Using Triptolide-Loaded NGR-functionalized Liposomes for Enhanced Cancer Radiotherapy

Radiosensitizer-based Injectable Hydrogel for Enhanced Radio-Chemotherapy of TNBC

Tumor-penetrating peptide internalizing RGD enhances radiotherapy efficacy through reducing tumor hypoxia

RGD peptide-modified fluorescent gold nanoclusters as highly efficient tumor-targeted radiotherapy sensitizers

Physiologically triggered injectable red blood cell-based gel for tumor photoablation and enhanced cancer immunotherapy

Construction of Nucleus-Targeting Iridium Nanocrystals for Photonic Hyperthermia-Synergized Cancer Radiotherapy

Enhancement Of Radiotherapy Efficacy By Mir-200c-Loaded Gelatinase-Stimuli Peg-Pep-Pcl Nanoparticles In Gastric Cancer Cells

Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.

Effective Triple-Negative Breast Cancer Targeted Treatment Using iRGD-Modified RBC Membrane-Camouflaged Nanoparticles

Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment

Camouflaging Irgd-Egfr Anchored Human Cytotoxic T-lymphocyte Membranes to the Surface of Nanoparticles Combined with Low-Dose Irradiation: New Approach to Enhance Drug-Delivery Targeting in Gastric Cancer

Irgd-Functionalized PEGylated Nanoparticles for Enhanced Colon Tumor Accumulation and Targeted Drug Delivery

Erythrocyte membrane-camouflaged gefitinib/albumin nanoparticles for tumor imaging and targeted therapy against lung cancer

Crgd Conjugated Mpeg-Plga-pll Nanoparticles for SGC-7901 Gastric Cancer Cells-Targeted Delivery of Fluorouracil.

Low-dose radiotherapy synergizes with iRGD-antiCD3-modified T cells by facilitating T cell infiltration

The enhancement effect of internalization RGD motif on the 18F-FDG uptake of 4T1 breast cancer in mice

Tumor‑penetrating Peptide Fused EGFR Single‑domain Antibody Enhances Radiation Responses Following EGFR Inhibition in Gastric Cancer.

An Experimental Study On Targeted Therapy Of Radioiodinated Cyclic Crgd Peptide On Melanoma Bearing Mice

Bispecific tumor-penetrating protein anti-EGFR-iRGD efficiently enhances the infiltration of lymphocytes in gastric cancer.

Biodistribution and Toxicity Assessment of Intratumorally Injected Arginine-Glycine-aspartic Acid Peptide Conjugated to CdSe/ZnS Quantum Dots in Mice Bearing Pancreatic Neoplasm